{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T13:15:19Z","timestamp":1756991719079,"version":"3.41.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ucl.2025.01.005","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T21:15:04Z","timestamp":1741295704000},"page":"229-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pheochromocytoma and Paragangliomas"],"prefix":"10.1016","volume":"52","author":[{"given":"Reuben","family":"Ben-David","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Eraky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Mehrazin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Waingankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ucl.2025.01.005_bib1","article-title":"Systematic review: incidence of pheochromocytoma and paraganglioma over 70 years","volume":"6","author":"Al Subhi","year":"2022","journal-title":"J\u00a0Endocr Soc"},{"issue":"12","key":"10.1016\/j.ucl.2025.01.005_bib2","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.neurobiolaging.2008.12.001","article-title":"Morphophysiology of the Zuckerkandl\u2019s paraganglion: effects of dexamethasone and aging","volume":"31","author":"Ramiro-Fuentes","year":"2010","journal-title":"Neurobiol Aging"},{"issue":"1","key":"10.1016\/j.ucl.2025.01.005_bib3","first-page":"R65","article-title":"Pheochromocytoma and paraganglioma: germline genetics and hereditary syndromes","volume":"2","author":"Turin","year":"2022","journal-title":"Endocr Oncol (Bristol, England)"},{"key":"10.1016\/j.ucl.2025.01.005_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1021420","article-title":"Silent pheochromocytoma and paraganglioma: systematic review and proposed definitions for standardized terminology","volume":"13","author":"Constantinescu","year":"2022","journal-title":"Front Endocrinol"},{"issue":"5","key":"10.1016\/j.ucl.2025.01.005_bib5","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1210\/endrev\/bnad011","article-title":"Biochemical assessment of pheochromocytoma and paraganglioma","volume":"44","author":"Eisenhofer","year":"2023","journal-title":"Endocr Rev"},{"issue":"12","key":"10.1016\/j.ucl.2025.01.005_bib6","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1245\/s10434-013-3142-z","article-title":"Discriminating pheochromocytomas from other adrenal lesions: the dilemma of elevated catecholamines","volume":"20","author":"Carr","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.ucl.2025.01.005_bib7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41574-021-00492-3","article-title":"International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers","volume":"17","author":"Amar","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.ucl.2025.01.005_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s12672-021-00404-x","article-title":"Metastatic pheochromocytoma and paraganglioma: signs and symptoms related to catecholamine secretion","volume":"12","author":"Li","year":"2021","journal-title":"Discov Oncol"},{"issue":"8","key":"10.1016\/j.ucl.2025.01.005_bib9","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/HJH.0000000000002438","article-title":"Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension","volume":"38","author":"Lenders","year":"2020","journal-title":"J\u00a0Hypertens"},{"issue":"3","key":"10.1016\/j.ucl.2025.01.005_bib10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1530\/EJE-14-0730","article-title":"Measurements of plasma metanephrines by immunoassay vs liquid chromatography with tandem mass spectrometry for diagnosis of pheochromocytoma","volume":"172","author":"Weismann","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"10.1016\/j.ucl.2025.01.005_bib11","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/jama.287.11.1427","article-title":"Biochemical diagnosis of pheochromocytoma: which test is best?","volume":"287","author":"Lenders","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ucl.2025.01.005_bib12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cca.2018.12.019","article-title":"Reference intervals for LC-MS\/MS measurements of plasma free, urinary free and urinary acid-hydrolyzed deconjugated normetanephrine, metanephrine and methoxytyramine","volume":"490","author":"Eisenhofer","year":"2019","journal-title":"Clin Chim Acta"},{"issue":"4","key":"10.1016\/j.ucl.2025.01.005_bib13","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/cen.12327","article-title":"Biochemical diagnosis of phaeochromocytoma using plasma-free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions","volume":"80","author":"D\u00e4rr","year":"2014","journal-title":"Clin Endocrinol"},{"issue":"6","key":"10.1016\/j.ucl.2025.01.005_bib14","article-title":"Pitfalls in the diagnostic evaluation of pheochromocytomas","volume":"8","author":"Fagundes","year":"2024","journal-title":"J\u00a0Endocr Soc"},{"issue":"11","key":"10.1016\/j.ucl.2025.01.005_bib15","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1373\/clinchem.2018.291369","article-title":"Biochemical diagnosis of chromaffin cell tumors in patients at high and low risk of disease: plasma versus urinary free or deconjugated o-methylated catecholamine metabolites","volume":"64","author":"Eisenhofer","year":"2018","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/j.ucl.2025.01.005_bib16","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"N\u00f6lting","year":"2022","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.ucl.2025.01.005_bib17","first-page":"318","article-title":"Chromogranin A in a cohort of pheochromocytomas and paragangliomas: usefulness at diagnosis and as an early biomarker of recurrence","volume":"27","author":"Parisien-La Salle","year":"2021","journal-title":"Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"issue":"10","key":"10.1016\/j.ucl.2025.01.005_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101505","article-title":"Current management of pheochromocytoma\/paraganglioma: a guide for the practicing clinician in the era of precision medicine","volume":"11","author":"N\u00f6lting","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ucl.2025.01.005_bib19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jmsacl.2021.08.001","article-title":"A\u00a0high sensitivity LC-MS\/MS method for measurement of 3-methoxytyramine in plasma and associations between 3-methoxytyramine, metanephrines, and dopamine","volume":"21","author":"Smy","year":"2021","journal-title":"J\u00a0mass Spectrom Adv Clin lab"},{"issue":"5","key":"10.1016\/j.ucl.2025.01.005_bib20","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/cen.14724","article-title":"Clonidine suppression test for a reliable diagnosis of pheochromocytoma: when to use","volume":"97","author":"Tsiomidou","year":"2022","journal-title":"Clin Endocrinol"},{"issue":"6","key":"10.1016\/j.ucl.2025.01.005_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-228263","article-title":"Clonidine suppression testing for pheochromocytoma in neurofibromatosis type 1","volume":"12","author":"Wan","year":"2019","journal-title":"BMJ Case Rep"},{"issue":"1","key":"10.1016\/j.ucl.2025.01.005_bib22","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-23-0063","article-title":"False-positive results for pheochromocytoma associated with norepinephrine reuptake blockade","volume":"31","author":"Sch\u00fcrfeld","year":"2024","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"10.1016\/j.ucl.2025.01.005_bib23","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1161\/HYPERTENSIONAHA.122.19019","article-title":"Improved diagnostic accuracy of clonidine suppression testing using an age-related cutoff for plasma normetanephrine","volume":"79","author":"Remde","year":"2022","journal-title":"Hypertens (Dallas, Tex 1979)"},{"issue":"8","key":"10.1016\/j.ucl.2025.01.005_bib24","doi-asserted-by":"crossref","first-page":"e2900","DOI":"10.1210\/clinem\/dgab241","article-title":"Properly collected plasma metanephrines excludes PPGL after false-positive screening tests","volume":"106","author":"Kline","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ucl.2025.01.005_bib25","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.amjsurg.2020.04.021","article-title":"Utility of the 10 Hounsfield unit threshold for identifying adrenal adenomas: can we improve?","volume":"220","author":"Kirsch","year":"2020","journal-title":"Am J Surg"},{"issue":"3","key":"10.1016\/j.ucl.2025.01.005_bib26","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1148\/radiol.2493070976","article-title":"Incidental adrenal lesions: principles, techniques, and algorithms for imaging characterization","volume":"249","author":"Boland","year":"2008","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.ucl.2025.01.005_bib27","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.euf.2015.09.011","article-title":"Pheochromocytoma in urologic practice","volume":"1","author":"Waingankar","year":"2016","journal-title":"Eur Urol Focus"},{"issue":"3","key":"10.1016\/j.ucl.2025.01.005_bib28","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s00330-017-5076-5","article-title":"Pheochromocytoma as a frequent false-positive in adrenal washout CT: a systematic review and meta-analysis","volume":"28","author":"Woo","year":"2018","journal-title":"Eur Radiol"},{"issue":"8","key":"10.1016\/j.ucl.2025.01.005_bib29","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0009-9260(97)80252-8","article-title":"MR differentiation of phaeochromocytoma from other adrenal lesions based on qualitative analysis of T2 relaxation times","volume":"52","author":"Varghese","year":"1997","journal-title":"Clin Radiol"},{"issue":"Suppl 3","key":"10.1016\/j.ucl.2025.01.005_bib30","doi-asserted-by":"crossref","first-page":"S223","DOI":"10.21037\/gs.2019.06.02","article-title":"Magnetic resonance imaging of adrenal gland: state of the art","volume":"8","author":"d\u2019Amuri","year":"2019","journal-title":"Gland Surg"},{"issue":"6","key":"10.1016\/j.ucl.2025.01.005_bib31","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.2214\/AJR.16.17758","article-title":"Update on CT and MRI of adrenal nodules","volume":"208","author":"Schieda","year":"2017","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ucl.2025.01.005_bib32","unstructured":"Itani M, Mhlanga J. Chapter 3: Imaging of pheochromocytoma and paraganglioma. In: Mariani-Costantini R, editor. Codon Publications; Brisbane (AU); 2019. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK543223\/."},{"issue":"2B","key":"10.1016\/j.ucl.2025.01.005_bib33","first-page":"1599","article-title":"Iodine-123 metaiodobenzylguanidine scintigraphy in localising phaeochromocytomas--experience and meta-analysis","volume":"26","author":"Der Horst-Schrivers ANA","year":"2006","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.ucl.2025.01.005_bib34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/RLU.0000000000004963","article-title":"A\u00a0prospective comparative study of 18 F-FDOPA PET\/CT versus 123 I-MIBG scintigraphy with SPECT\/CT for the diagnosis of pheochromocytoma and paraganglioma","volume":"49","author":"Sung","year":"2024","journal-title":"Clin Nucl Med"},{"issue":"17","key":"10.1016\/j.ucl.2025.01.005_bib35","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1158\/1078-0432.CCR-14-2751","article-title":"Superiority of\u00a0[68Ga]-DOTATATE PET\/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma","volume":"21","author":"Janssen","year":"2015","journal-title":"Clin cancer Res an Off J Am Assoc Cancer Res"},{"issue":"3","key":"10.1016\/j.ucl.2025.01.005_bib36","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1210\/endrev\/bnae001","article-title":"Imaging of pheochromocytomas and paragangliomas","volume":"45","author":"Timmers","year":"2024","journal-title":"Endocr Rev"},{"issue":"9","key":"10.1016\/j.ucl.2025.01.005_bib37","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/jnci\/djs188","article-title":"Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography","volume":"104","author":"Timmers","year":"2012","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.ucl.2025.01.005_bib38","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/SLA.0000000000002671","article-title":"Preoperative 18F-FDG PET\/CT in pheochromocytomas and paragangliomas allows for precision surgery","volume":"269","author":"Nockel","year":"2019","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.ucl.2025.01.005_bib39","first-page":"22","article-title":"(68)Ga-DOTATATE and (18)F-FDG PET\/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity","volume":"16","author":"Chang","year":"2016","journal-title":"Cancer imaging Off Publ Int Cancer Imaging Soc"},{"issue":"3","key":"10.1016\/j.ucl.2025.01.005_bib40","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2967\/jnumed.116.180430","article-title":"Head-to-head comparison of (64)Cu-DOTATATE and (68)Ga-DOTATOC PET\/CT: a Prospective Study of 59 patients with neuroendocrine tumors","volume":"58","author":"Johnbeck","year":"2017","journal-title":"J\u00a0Nucl Med"},{"issue":"16","key":"10.1016\/j.ucl.2025.01.005_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14163886","article-title":"Performances of functional and anatomic imaging modalities in succinate dehydrogenase a-related metastatic pheochromocytoma and paraganglioma","volume":"14","author":"Patel","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.ucl.2025.01.005_bib42","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/cen.13737","article-title":"Role of DOTATATE-PET\/CT in preoperative assessment of phaeochromocytoma and paragangliomas","volume":"89","author":"Gild","year":"2018","journal-title":"Clin Endocrinol"},{"issue":"7","key":"10.1016\/j.ucl.2025.01.005_bib47","doi-asserted-by":"crossref","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Shah","year":"2021","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"issue":"6","key":"10.1016\/j.ucl.2025.01.005_bib43","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ejhg.2010.175","article-title":"von Hippel-Lindau disease: a clinical and scientific review","volume":"19","author":"Maher","year":"2011","journal-title":"Eur J Hum Genet"},{"issue":"11","key":"10.1016\/j.ucl.2025.01.005_bib44","doi-asserted-by":"crossref","first-page":"R293","DOI":"10.1530\/EC-21-0294","article-title":"Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: not a needle in a haystack","volume":"10","author":"Castro-Teles","year":"2021","journal-title":"Endocr Connect"},{"issue":"3","key":"10.1016\/j.ucl.2025.01.005_bib45","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/ejhg.2016.173","article-title":"Prevalence, birth incidence, and penetrance of von Hippel-Lindau disease (vHL) in Denmark","volume":"25","author":"Binderup","year":"2017","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"10.1016\/j.ucl.2025.01.005_bib46","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/BF03347089","article-title":"Pediatric endocrine screening for von Hippel-Lindau disease: benefits and the challenge of compliance","volume":"34","author":"Prasad","year":"2011","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"3","key":"10.1016\/j.ucl.2025.01.005_bib48","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s12020-020-02332-2","article-title":"MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives","volume":"69","author":"Amodru","year":"2020","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.ucl.2025.01.005_bib49","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-8587(18)30336-X","article-title":"Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study","volume":"7","author":"Castinetti","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.ucl.2025.01.005_bib50","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1093\/ejendo\/lvad066","article-title":"European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"189","author":"Fassnacht","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.ucl.2025.01.005_bib51","first-page":"8","article-title":"Surgical indications and techniques for adrenalectomy","volume":"54","author":"Uluda\u011f","year":"2020","journal-title":"Sisli Etfal Hastan tip Bul"},{"key":"10.1016\/j.ucl.2025.01.005_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1127676","article-title":"Total versus partial adrenalectomy in bilateral pheochromocytoma - a systematic review and meta-analysis","volume":"14","author":"Zawadzka","year":"2023","journal-title":"Front Endocrinol"},{"issue":"4","key":"10.1016\/j.ucl.2025.01.005_bib53","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1089\/end.2023.0406","article-title":"Surgical technique and perioperative outcomes following single-port robotic adrenalectomy: a single institutional experience","volume":"38","author":"Rudnick","year":"2024","journal-title":"J\u00a0Endourol"},{"issue":"6","key":"10.1016\/j.ucl.2025.01.005_bib54","first-page":"991","article-title":"Laparoscopic adrenalectomy (LA) vs open adrenalectomy (OA) for pheochromocytoma (PHEO): a systematic review and meta-analysis","volume":"46","author":"Li","year":"2020","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2025.01.005_bib55","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12893-020-00824-6","article-title":"Laparoscopic versus open surgery for pheochromocytoma: a meta-analysis","volume":"20","author":"Fu","year":"2020","journal-title":"BMC Surg"},{"issue":"Suppl 1","key":"10.1016\/j.ucl.2025.01.005_bib56","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.21037\/gs.2019.05.10","article-title":"Open adrenalectomy","volume":"8","author":"Mihai","year":"2019","journal-title":"Gland Surg"},{"issue":"1","key":"10.1016\/j.ucl.2025.01.005_bib57","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12957-023-03164-w","article-title":"Which surgical approach is more favorable for pheochromocytoma of different sizes (< 6 cm vs. \u2265 6 cm)? A single retrospective center experience","volume":"21","author":"Wan","year":"2023","journal-title":"World J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2025.01.005_bib58","first-page":"115","article-title":"Comparison of clinical efficacy and safety between robotic-assisted and laparoscopic adrenalectomy for pheochromocytoma: a systematic review and meta-analysis","volume":"18","author":"Wang","year":"2024","journal-title":"J\u00a0Robot Surg"},{"issue":"4","key":"10.1016\/j.ucl.2025.01.005_bib59","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.suc.2024.02.014","article-title":"Management of pheochromocytomas and paragangliomas","volume":"104","author":"Passman","year":"2024","journal-title":"Surg Clin North Am"},{"issue":"4","key":"10.1016\/j.ucl.2025.01.005_bib60","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41574-023-00929-x","article-title":"Iatrogenic adrenal insufficiency in adults","volume":"20","author":"Martin-Grace","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"10.1016\/j.ucl.2025.01.005_bib61","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/MPA.0000000000001792","article-title":"The North American neuroendocrine tumor society consensus guidelines for surveillance and management of metastatic and\/or unresectable pheochromocytoma and paraganglioma","volume":"50","author":"Fishbein","year":"2021","journal-title":"Pancreas"},{"issue":"5","key":"10.1016\/j.ucl.2025.01.005_bib62","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity (131)I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J\u00a0Nucl Med"},{"issue":"9","key":"10.1016\/j.ucl.2025.01.005_bib63","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1530\/EC-20-0292","article-title":"177Lu-DOTATATE therapy in metastatic\/inoperable pheochromocytoma-paraganglioma","volume":"9","author":"Jaiswal","year":"2020","journal-title":"Endocr Connect"},{"issue":"7","key":"10.1016\/j.ucl.2025.01.005_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11070909","article-title":"Favorable outcome in patients with pheochromocytoma and paraganglioma treated with (177)Lu-DOTATATE","volume":"11","author":"Vyakaranam","year":"2019","journal-title":"Cancers"},{"issue":"10431","key":"10.1016\/j.ucl.2025.01.005_bib65","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0140-6736(23)02554-0","article-title":"Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial","volume":"403","author":"Baudin","year":"2024","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10.1016\/j.ucl.2025.01.005_bib66","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S1470-2045(24)00133-5","article-title":"Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial","volume":"25","author":"Jimenez","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2025.01.005_bib67","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1007\/s12020-024-03700-y","article-title":"Treatment of metastatic paraganglioma: experience of a single center","volume":"84","author":"Ver\u00edssimo","year":"2024","journal-title":"Endocrine"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014325000059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014325000059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T18:34:08Z","timestamp":1750185248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014325000059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0094014325000059"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2025.01.005","relation":{},"ISSN":["0094-0143"],"issn-type":[{"type":"print","value":"0094-0143"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pheochromocytoma and Paragangliomas","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2025.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}